Rockwell Medical, Inc.

RMTI

Healthcare Drug Manufacturers Specialty & Generic

Rockwell Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.3 million, down 31.8% from fiscal 2024.

Revenue
+10.6%
EPS
+32.0%
Free cash flow
−12.9%
Total debt
−1.73%

Quarter to June 2026, against a year earlier

7.73 0.13 +1.71%
Market cap
$31.2M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
3/9
ROIC
−14.6%
Net debt / EBITDA
7.4×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(15.53%) (16.04%) (15.28%) (17.14%)

+8 more TTM periods

Piotroski F-Score
5 4 3 3
ROA
(9.32%) (9.70%) (9.13%) (9.90%)
ROIC
(14.58%) (14.27%) (13.89%) (13.38%)
Return on Tangible Assets
(17.06%) (17.21%) (16.00%) (17.24%)
Average Days of Receivables
43.69 47.59 42.91 40.22
Free Cash Flow per Share
0.43 0.49 (0.33) (0.81)
Free Cash Flow
1.72 1.93 (1.20) (2.94)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026